{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:36:52Z","timestamp":1760747812012,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ejca.2022.10.019","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T03:15:11Z","timestamp":1667358911000},"page":"180-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti\u2013programmed death-1 therapy"],"prefix":"10.1016","volume":"178","author":[{"given":"Shahneen","family":"Sandhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Gonz\u00e1lez","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4673-8989","authenticated-orcid":false,"given":"Ainara Soria","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5471-4901","authenticated-orcid":false,"given":"Ivor","family":"Caro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuyao","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yibing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cloris","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-3545","authenticated-orcid":false,"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2022.10.019_bib1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/s40425-019-0780-0","article-title":"Secondary resistance to immunotherapy associated with \u03b2-catenin pathway activation or PTEN loss in metastatic melanoma","volume":"7","author":"Trujillo","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2022.10.019_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J Transl Med"},{"issue":"7","key":"10.1016\/j.ejca.2022.10.019_bib3","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","year":"2015","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.ejca.2022.10.019_bib4","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","article-title":"Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function","volume":"70","author":"Boni","year":"2010","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2022.10.019_bib5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2022.10.019_bib6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.immuni.2016.01.024","article-title":"MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade","volume":"44","author":"Ebert","year":"2016","journal-title":"Immunity"},{"issue":"20","key":"10.1016\/j.ejca.2022.10.019_bib7","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"issue":"10030","key":"10.1016\/j.ejca.2022.10.019_bib8","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"issue":"10031","key":"10.1016\/j.ejca.2022.10.019_bib9","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.ejca.2022.10.019_bib10","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1158\/1078-0432.CCR-18-3488","article-title":"Safety, clinical activity, and biological correlates of response in patients with metastatic melanoma: results from a phase I trial of atezolizumab","volume":"25","author":"Hamid","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ejca.2022.10.019_bib11","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/annonc\/mdz113","article-title":"Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors","volume":"30","author":"Hellmann","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2022.10.019_bib12","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/pcmr.12960","article-title":"First-line atezolizumab monotherapy in patients with advanced BRAF(V600) wild-type melanoma","volume":"34","author":"de Azevedo","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"issue":"7","key":"10.1016\/j.ejca.2022.10.019_bib13","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","article-title":"The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4","volume":"21","author":"Liu","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2022.10.019_bib14","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1158\/1078-0432.CCR-15-1125","article-title":"RAS\/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1\/PD-L1 immune checkpoint inhibitors","volume":"22","author":"Loi","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2022.10.019_bib15","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/jco.2015.33.15_suppl.3003","article-title":"Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and\/or MEK (trametinib) inhibitors in advanced melanoma","volume":"33","author":"Ribas","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2022.10.019_bib16","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.annonc.2020.12.004","article-title":"Cobimetinib plus atezolizumab in BRAF(V600) wild-type melanoma: primary results from the randomized phase III IMspire170 study","volume":"32","author":"Gogas","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.10.019_bib17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2017.01.009","article-title":"Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma","volume":"75","author":"Zimmer","year":"2017","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2022.10.019_bib18","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S1470-2045(21)00097-8","article-title":"Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study","volume":"22","author":"da Silva","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2022.10.019_bib19","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1007\/s12094-021-02598-6","article-title":"Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis","volume":"23","author":"Alrabadi","year":"2021","journal-title":"Clin Transl Oncol"},{"issue":"suppl_15","key":"10.1016\/j.ejca.2022.10.019_bib20","article-title":"Phase II trial of pembrolizumab (pembro) plus 1mg\/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel)","volume":"36","author":"Olson","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2022.10.019_bib21","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.10004","article-title":"Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial","volume":"38","author":"Olson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2022.10.019_bib22","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/2326-6066.CIR-16-0143","article-title":"Targeted next generation sequencing identifies markers of response to PD-1 blockade","volume":"4","author":"Johnson","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"10.1016\/j.ejca.2022.10.019_bib23","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.3390\/cancers11111798","article-title":"Tumor mutational burden and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"11","author":"Kim","year":"2019","journal-title":"Cancers"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2022.10.019_bib24","article-title":"Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy","volume":"38","author":"Da Silva","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2022.10.019_bib25","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2022.10.019_bib26","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejca.2022.10.019_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418799864","article-title":"Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system","volume":"11","author":"Dalakas","year":"2018","journal-title":"Ther Adv Neurol Disord"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922013223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922013223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:39:32Z","timestamp":1760733572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922013223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":27,"alternative-id":["S0959804922013223"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.10.019","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti\u2013programmed death-1 therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}